Abstract

Twenty years after the epidermal growth factor receptor (EGFR) was identified as a potential anticancer target, the EGFR inhibitor gefitinib (Iressa; AstraZeneca) has been approved for the treatment of patients with advanced non-small-cell lung cancer in many countries. Studies have indicated its potential for treating patients with other types of solid tumours. Investigation of gefitinib has not only increased our knowledge about the biology of EGFR signalling, but is contributing to our evolving understanding of which tumours are EGFR dependent.

Author affiliations

1. Roy S. Herbst is at the Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 432, Houston, Texas 77030, USA.
2. Masahiro Fukuoka is at the Department of Medical Oncology, Kinki University School of Medicine, 377-2, Ohno-higashi, Osakasayama City, Osaka 589-8511, Japan.
3. José Baselga is at the Medical Oncology Service, Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona, P Vall d'Hebron 119-129, 08035 Barcelona, Spain.

Correspondence to: Roy S. Herbst¹ Email: rherbst@mdanderson.org

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.